



PATENT
ATTORNEY DOCKET NO. 50285/003002

Certificate of Mailing: Date of Deposit: 1/9/04

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being hand delivered to Art Unit 1646, Technology Center 1600, U.S. Patent and Trademark Office, Washington, D.C. 20231.

Jewel Smith

Printed name of person hand delivering correspondence

Signature of person hand delivering correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Timothy S. Leach et al. Art Unit: 1646

Serial No.: 10/650,099 Examiner: Not yet assigned

Filed: August 25, 2003 Customer No.: 21559

Title: METHODS AND REAGENTS FOR PREVENTING
BACTEREMIAS

Art Unit 1646

Technology Center 1600

U.S. Patent and Trademark Office

Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.


This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date: Jan. 7, 2004



Paul T. Clark
Reg. No. 30,162

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



Sheet 1 of 2

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				Attorney Docket No.	50285/003002		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Serial No.	10/650,099		
(37 C.F.R. § 1.98(b))				Applicant	Timothy S. Leach et al.		
				Filing Date	August 25, 2003		
				Group	1646		
				IDS Filed	January 9, 2004		
				Customer No.	21559		
U.S. PATENTS							
Examiner's Initials	Patent Number	Issue Date	Patentee		Class	Subclass	Filing Date (If Appropriate)
	4,303,646	12/01/81	Cavalleri et al.		424	118	
	4,328,316	05/04/82	Cavalleri et al.		435	253	
	4,427,656	01/24/84	Cavalleri et al.		424	118	
	5,108,988	04/28/92	Ciabatti et al.		514	11	
	5,491,128	02/13/96	Ciabatti et al.		514	11	
	5,539,087	07/23/96	Restelli et al.		530	412	
	5,752,941	05/19/98	Romano' et al.		604	265	
	5,925,550	07/20/99	Lancini et al.		435	71.3	
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION							
Examiner's Initials	Document Number	Publication Date	Country or Patent Office		Class	Subclass	Translation (Yes/No)
	WO 99/30690	06/24/99	PCT				
	WO 01/44271 A2	06/21/01	PCT				
	WO 01/44272 A2	06/21/01	PCT				
	WO 01/44274 A1	06/21/01	PCT				
	WO 01/53330 A2	07/26/01	PCT				
	WO 01/70213 A2	09/27/01	PCT				
	WO 01/97851 A2	12/27/01	PCT				
	WO 02/05838 A1	01/24/02	PCT				
	WO 02/15959 A2	02/28/02	PCT				
	WO 02/056829 A2	07/25/02	PCT				
EXAMINER			DATE CONSIDERED				
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.							



Sheet 2 of 2

SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50285/003002
			Serial No.	10/650,099
			Applicant	Timothy S. Leach et al.
			Filing Date	August 25, 2003
			Group	1646
			IDS Filed	January 9, 2004
			Customer No.	21559
(37 C.F.R. § 1.98(b))				

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 02/059145 A1	08/01/02	PCT			
	WO 02/059322 A2	08/01/02	PCT			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	Baden et al., "Molecular characterization of vancomycin-resistant enterococci repopulating the gastrointestinal tract following treatment with a novel glycolipodepsipeptide, ramoplanin," <i>J. Clinical Microbiol.</i> , 40:1160-1163 (2002).
	Bartlett, "Treatment of antibiotic-associated pseudomembranous colitis," <i>Reviews of Infectious Diseases</i> 6(Suppl 1):S235-S241 (1984).
	Biavasco et al., "In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of <i>Clostridium difficile</i> ," <i>Antimicrobial Agents and Chemotherapy</i> 35:195-197 (1991).
	Citron et al., "In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria," <i>Antimicrobial Agents and Chemotherapy</i> 47:2334-2338 (2003).
	Hassan et al., "In vitro activity of teicoplanin, vancomycin, A16686, clindamycin, erythromycin and fusidic acid against anaerobic bacteria," <i>Singapore Med. J.</i> 31:56-58 (1990).
	Neu et al., "In vitro activity of A-16686, a new glycopeptide," <i>Chemotherapy</i> 32:453-457 (1986).
	O'Hare et al., "In vitro activity of A-16686 - A novel glycopeptide active against gram positive bacteria," <i>15th International Congress of Chemotherapy</i> , (Abstract 390) 1987.
	O'Hare et al., "In-vitro studies with ramoplanin (MDL 62,198): a novel lipoglycopeptide antimicrobial," <i>J. Antimicrobial Chemotherapy</i> 25:217-220 (1990).
	Ravizzola et al., "Attività' antibatterica di un nuovo glicopeptide A-16686 nei confronti di microorganismi gram-positivi," <i>Biol. Microbiol. Lab</i> 4:51-56 (1987). (English abstract)
	Ravizzola et al., A-16686, a new glycopeptide: <i>in vitro</i> evaluation in comparison with other antibiotics," <i>J. Chemother.</i> 1(Suppl. 4):212-213 (1989).
	Wong et al., "Effective suppression of vancomycin-resistant <i>Enterococcus</i> species in asymptomatic gastrointestinal carriers by a novel glycolipodepsipeptide, ramoplanin," <i>Clin. Infect. Dis.</i> 33:1476-1482 (2001).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.